Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Motif Bio notes statement from Amphion Innovations

21 Aug 2018 07:15

RNS Number : 3946Y
Motif Bio PLC
21 August 2018
 

Motif Bio plc

("Motif Bio" or the "Company")

 

Motif Bio notes statement from Amphion Innovations

 

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, notes the announcement made today via RNS by Amphion Innovations plc ("Amphion"), a substantial shareholder in the Company, relating to its sale of shares in Motif Bio to an institutional investor. Amphion now holds 8.51% of the issued share capital of Motif Bio. The full TR-1 disclosure is set out below.

 

For further information please contact:

 

Motif Bio plc

info@motifbio.com

Graham Lumsden (Chief Executive Officer)

 

 

 

 

 

Peel Hunt LLP (NOMAD & BROKER)

+ 44 (0)20 7418 8900

Dr Christopher Golden

 

Oliver Jackson

 

 

 

 

 

Northland Capital Partners Limited (BROKER)

+44 (0)20 3861 6625

David Hignell/Vadim Alexandre/Rob Rees

 

 

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/Helen Cresswell/Lianne Cawthorne

motifbio@walbrookpr.com

 

 

 

 

 

 

MC Services AG (EUROPEAN IR)

+49 (0) 89 210 2280

Raimund Gabriel

raimund.gabriel@mc-services.eu

 

 

 

 

Solebury Trout (U.S. IR)

+ 1 (646) 378-2963

Meggie Purcell

mpurcell@troutgroup.com

 

 

 

 

 

Russo Partners (U.S. PR)

+1 (858) 717-2310 or +1 (212) 845 4272

David Schull

david.schull@russopartnersllc.com

Travis Kruse, Ph.D.

travis.kruse@russopartnersllc.com

 

 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Motif Bio plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Amphion Innovations plc

City and country of registered office (if applicable)

 

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

August 20 2018

6. Date on which issuer notified (DD/MM/YYYY):

August 20 2018

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

8.51%

 

 

296,660,243

Position of previous notification (if

applicable)

9.53%

 

 

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB008BVVT4H71

25,254,611

 

8.51%

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

25,254,611

8.51%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

United Kingdom

Date of completion

August 20 2018

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLSELSIFFASEIA
Date   Source Headline
1st Jul 20155:07 pmRNSHolding(s) in Company
23rd Jun 20158:47 amRNSPartner Company raises £22 million
23rd Jun 20157:00 amRNSPreliminary Results
5th Jun 20157:00 amRNSPlacing to raise £1.54 million
19th May 20152:35 pmRNSAppointment of broker
15th Apr 20157:01 amRNSFDA Results
7th Apr 20157:00 amRNSShares Issued for Exercised Warrants
2nd Apr 20157:01 amRNSFirst Day of Dealings of Amphion Partner Company
24th Mar 20153:28 pmRNSIssue of Shares
20th Mar 20157:01 amRNSMotif Bio Ltd Update Re Intention to Float
26th Feb 20157:00 amRNSIssue of Equity
9th Feb 20157:00 amRNSDirector/PDMR Shareholding
2nd Feb 20154:18 pmRNSReissue: Partner Company's Intention to Float
2nd Feb 20158:00 amRNSPartner Company's Intention to Float on AIM
22nd Jan 20151:15 pmRNSDirector/PDMR Shareholding
19th Jan 20157:00 amRNSLandmark Acquisition & Update by Partner Company
6th Jan 20157:00 amRNSDataTern Receives Favourable Appeal Ruling
24th Sep 20147:00 amRNSDirectors' Dealings
19th Sep 20147:00 amRNSHalf Yearly Report
9th Sep 20147:00 amRNSAdditional Draws on Loan Facility
28th Aug 20147:00 amRNSDirectorate Change
7th Aug 20144:51 pmRNSResult of AGM and EGM
10th Jul 20149:10 amRNSDirectors' Dealings
8th Jul 20147:00 amRNSAmphion Partner Motif Can Help Solve Health Crisis
20th Jun 20147:00 amRNSNotice of EGM
18th Jun 20147:00 amRNSFinal Results
5th Jun 20147:00 amRNSNew Loan Facility
14th Apr 20147:00 amRNSAppeal Ruling
7th Apr 20145:03 pmRNSDirector/PDMR Shareholding
28th Jan 20147:00 amRNSConvertible Promissory Note Extension
12th Dec 20137:00 amRNSUpdate on Covertible Promissory Note
13th Nov 20134:33 pmRNSDirector/PDMR Shareholding
13th Nov 20137:00 amRNSPartner Company Update
16th Oct 20137:02 amRNSPartner Company IPO
24th Sep 20137:00 amRNSHalf Yearly Report
12th Sep 20137:02 amRNSPartner company Kromek seeks IPO on AIM
13th Aug 20135:16 pmRNSResult of AGM
1st Jul 201312:02 pmRNSDirector/PDMR Shareholding
28th Jun 20137:00 amRNSFinal Results
18th Apr 20137:00 amRNSDirector/PDMR Shareholding
17th Apr 20137:00 amRNSTrading Statement
28th Mar 20137:02 amRNSChange of Adviser
19th Dec 20127:00 amRNSHolding(s) in Company
13th Dec 20127:00 amRNSFundraising
5th Dec 20127:00 amRNSAmphion announces new partnership with Motif
3rd Oct 20127:00 amRNSDirector/PDMR Shareholding
28th Sep 20124:24 pmRNSDirector/PDMR Shareholding
19th Sep 20127:00 amRNSHalf Yearly Report
29th Aug 20127:00 amRNSUpdate - patent litigation
27th Jul 20127:00 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.